A single-center, real world, retrospective study analyzing efficacy and safety of neoadjuvant immunotherapy in patients in colon cancer
Latest Information Update: 23 Feb 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Colon cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Feb 2023 New trial record
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium